KR102632743B1 - Composition for strengthening skin barrier containing Ganoderma lucidum extract as an active ingredient - Google Patents
Composition for strengthening skin barrier containing Ganoderma lucidum extract as an active ingredient Download PDFInfo
- Publication number
- KR102632743B1 KR102632743B1 KR1020230091896A KR20230091896A KR102632743B1 KR 102632743 B1 KR102632743 B1 KR 102632743B1 KR 1020230091896 A KR1020230091896 A KR 1020230091896A KR 20230091896 A KR20230091896 A KR 20230091896A KR 102632743 B1 KR102632743 B1 KR 102632743B1
- Authority
- KR
- South Korea
- Prior art keywords
- present
- skin
- saponarin
- composition
- skin barrier
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 81
- 240000008397 Ganoderma lucidum Species 0.000 title claims abstract description 58
- 235000001637 Ganoderma lucidum Nutrition 0.000 title claims abstract description 58
- 239000000284 extract Substances 0.000 title claims abstract description 55
- 230000008591 skin barrier function Effects 0.000 title claims abstract description 31
- 238000005728 strengthening Methods 0.000 title claims abstract description 22
- 239000004480 active ingredient Substances 0.000 title claims description 20
- HGUVPEBGCAVWID-KETMJRJWSA-N 7-O-(beta-D-glucosyl)isovitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1O)[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 HGUVPEBGCAVWID-KETMJRJWSA-N 0.000 claims abstract description 50
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 50
- HGUVPEBGCAVWID-UHFFFAOYSA-N saponarin Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)C2C(C(O)C(O)C(CO)O2)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 HGUVPEBGCAVWID-UHFFFAOYSA-N 0.000 claims abstract description 50
- 239000002537 cosmetic Substances 0.000 claims abstract description 24
- 101710197055 Hyaluronan synthase 3 Proteins 0.000 claims description 19
- 101710197057 Hyaluronan synthase 1 Proteins 0.000 claims description 18
- 102100040203 Hyaluronan synthase 1 Human genes 0.000 claims description 17
- 102100031784 Loricrin Human genes 0.000 claims description 17
- 108010079309 loricrin Proteins 0.000 claims description 17
- 102100029425 Hyaluronan synthase 3 Human genes 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 230000014509 gene expression Effects 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 235000013305 food Nutrition 0.000 abstract description 18
- 230000036541 health Effects 0.000 abstract description 18
- 235000013376 functional food Nutrition 0.000 abstract description 17
- 230000004888 barrier function Effects 0.000 abstract description 13
- 239000000126 substance Substances 0.000 abstract description 11
- 210000003491 skin Anatomy 0.000 description 29
- 210000002510 keratinocyte Anatomy 0.000 description 17
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 14
- 229920002674 hyaluronan Polymers 0.000 description 14
- 229960003160 hyaluronic acid Drugs 0.000 description 14
- -1 flavone glucoside Chemical class 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 239000000796 flavoring agent Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 150000008442 polyphenolic compounds Chemical class 0.000 description 10
- 235000013824 polyphenols Nutrition 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 235000013355 food flavoring agent Nutrition 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 239000006071 cream Substances 0.000 description 8
- 231100000135 cytotoxicity Toxicity 0.000 description 8
- 230000003013 cytotoxicity Effects 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 101710128038 Hyaluronan synthase Proteins 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000654 additive Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 235000013373 food additive Nutrition 0.000 description 5
- 239000002778 food additive Substances 0.000 description 5
- 235000015203 fruit juice Nutrition 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 230000003020 moisturizing effect Effects 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 150000004804 polysaccharides Chemical class 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000037394 skin elasticity Effects 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 240000005979 Hordeum vulgare Species 0.000 description 4
- 235000007340 Hordeum vulgare Nutrition 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 235000012149 noodles Nutrition 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 101710197056 Hyaluronan synthase 2 Proteins 0.000 description 3
- 102100040206 Hyaluronan synthase 2 Human genes 0.000 description 3
- 229920002230 Pectic acid Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 210000000736 corneocyte Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000013538 functional additive Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000010318 polygalacturonic acid Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 102100028314 Filaggrin Human genes 0.000 description 2
- 101710088660 Filaggrin Proteins 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 235000013334 alcoholic beverage Nutrition 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000892 thaumatin Substances 0.000 description 2
- 235000010436 thaumatin Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000004379 Adrenomedullin Human genes 0.000 description 1
- 101800004616 Adrenomedullin Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000000541 Defensins Human genes 0.000 description 1
- 108010002069 Defensins Proteins 0.000 description 1
- 102000030805 Dermcidin Human genes 0.000 description 1
- 108010034929 Dermcidin Proteins 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241000173371 Garcinia indica Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 244000130592 Hibiscus syriacus Species 0.000 description 1
- 235000018081 Hibiscus syriacus Nutrition 0.000 description 1
- 101000952040 Homo sapiens Beta-defensin 1 Proteins 0.000 description 1
- 101000912247 Homo sapiens Beta-defensin 103 Proteins 0.000 description 1
- 101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 1
- 102000014509 cathelicidin Human genes 0.000 description 1
- 108060001132 cathelicidin Proteins 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 102000046975 human DEFB1 Human genes 0.000 description 1
- 102000055779 human DEFB103A Human genes 0.000 description 1
- 102000049262 human DEFB4A Human genes 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 102000007236 involucrin Human genes 0.000 description 1
- 108010033564 involucrin Proteins 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001373 regressive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008020 response regulators Proteins 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/591—Mixtures of compounds not provided for by any of the codes A61K2800/592 - A61K2800/596
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
Abstract
본 발명은 영지버섯 추출물 및 사포나린을 포함하는 피부장벽 강화용 조성물에 관한 것으로, 본 발명의 영지버섯 추출물과 사포나린을 함께 사용하는 경우, 영지버섯 추출물 또는 사포나린을 단독으로 사용하는 경우와 비교하여 피부 물리적 장벽 및 화학적 장벽 수준을 우수하게 증가시키므로, 피부장벽 강화용 화장료, 식품 또는 건강기능식품 조성물로서 사용될 수 있다.The present invention relates to a composition for strengthening the skin barrier containing a reishi mushroom extract and saponarin. When the reishi mushroom extract of the present invention and saponarin are used together, the case is compared with the case when the reishi mushroom extract or saponarin is used alone. Because it significantly increases the level of the skin's physical barrier and chemical barrier, it can be used as a cosmetic, food, or health functional food composition for strengthening the skin barrier.
Description
본 발명은 영지버섯(Ganoderma lucidum) 추출물을 유효성분으로 포함하는 피부장벽 강화용 조성물에 관한 것으로, 더욱 상세하게는 영지버섯 추출물과 폴리페놀의 일종인 사포나린(saponarin)을 함께 포함하는 피부장벽 강화용 조성물에 관한 것이다.The present invention relates to a composition for strengthening the skin barrier containing a reishi mushroom ( Ganoderma lucidum ) extract as an active ingredient, and more specifically, to a composition for strengthening the skin barrier containing both the reishi mushroom extract and saponarin, a type of polyphenol. It relates to a composition for use.
포유동물 피부의 표피(epidermis) 및 진피(dermis)는 각종 유형의 세포를 포함함으로써, 다양한 기능을 수행하고 다양한 화학적 조성물을 보유하고 있다. 이러한 각기 다른 피부층 간에는 다양한 지질이 다양한 농도로 존재한다. 구체적으로, 피부의 진피는 콜라겐과 기타의 단백질을 주로 생성하고 지질은 매우 소량을 생성하는 섬유아세포로 구성되어 있다. 이와는 반대로, 표피는 지질을 생성하는 반면 콜라겐은 실질적으로 생성하지 않는 각질 세포를 포함한다. 섬유아세포(fibroblast) 에 의해 생성된 콜라겐은 피부에 신장 강도를 부여하게 되는 반면, 각질세포에 의해 생성된 지질은 생조직과 외부와의 차단층을 형성하여 피부장벽기능을 수행한다.The epidermis and dermis of mammalian skin contain various types of cells, thereby performing various functions and having various chemical compositions. Various lipids exist in varying concentrations between these different skin layers. Specifically, the dermis of the skin is composed of fibroblasts that mainly produce collagen and other proteins and very small amounts of lipids. In contrast, the epidermis contains keratinocytes that produce lipids while producing virtually no collagen. Collagen produced by fibroblasts provides stretching strength to the skin, while lipids produced by keratinocytes perform a skin barrier function by forming a barrier layer between living tissue and the outside.
각질층 또는 피부 장벽(Stratum corneum, Skin barrier)은 죽은 각질세포(Coneocyte)와 세포간 지질(Intercellular lipid)로 구성되어 있고, 외부 자극으로부터 피부를 보호하며 피부에서 수분이 증발하는 것을 막아주는 피부 보호막으로서 피부건강에 핵심적인 기능을 담당한다. 특히, 피부의 수분 불투과성은 죽은 각질세포(corneocyte)와 세포간 지질에 의해 획득되는데, 죽은 각질세포의 표면을 구성하는 각질세포 외피(corneocyte envelope)는 세포간 지질의 안정성에 중요한 역할을 한다. 각질세포 외피는 인볼루크린(involucrin), 로리크린(loricrin), 필라그린(filaggrin) 등의 단백질 막으로 구성된다. 또한, 피부는 filaggrin에서 유래한 천연함습인자 외에도 hyaluronic acid(HA), urea, citrate, lactate, glycerol 등의 다양한 함습인자에 의해 보습장벽 기능을 수행한다. 이중 HA 는 분자량이 20-40만에 이르는 고분자화합물로써 표피의 수분 증발을 막아 피부의 탄력성을 유지할 뿐만 아니라, 영양성분의 저장과 확산, 세포 이동 등에 관여한다. HA는 주로 각질형성세포 및 섬유아세포(fibroblast)의 hyaluronic acid synthase(HAS)에 의해 합성되어 세포외기질에 축적된다. 지금까지 알려진 HAS 유전자는 HAS-1, HAS-2, HAS-3의 세 가지 형태가 보고 되었으며, 이들의 발현저하로 인한 보습장벽의 결함은 표피의 위축, 주름형성, 피부 수분량 감소, 탄력성 저하 등 피부노화를 일으키는 것으로 보고되었다. 이 중 HAS-3 유전자는 피부의 화학적 장벽 기능과 밀접한 연관이 있는 것으로 알려져 있다.The stratum corneum (Skin barrier) is composed of dead keratinocytes and intercellular lipids and is a skin protective film that protects the skin from external stimuli and prevents moisture from evaporating from the skin. It plays a key role in skin health. In particular, the water impermeability of the skin is achieved by dead corneocytes and intercellular lipids, and the corneocyte envelope, which constitutes the surface of dead corneocytes, plays an important role in the stability of intercellular lipids. The keratinocyte envelope is composed of a protein membrane such as involucrin, loricrin, and filaggrin. In addition, the skin performs a moisturizing barrier function through various moisturizing factors such as hyaluronic acid (HA), urea, citrate, lactate, and glycerol, in addition to natural moisturizing factors derived from filaggrin. Among them, HA is a polymer compound with a molecular weight ranging from 200,000 to 400,000. It not only maintains the elasticity of the skin by preventing moisture evaporation from the epidermis, but is also involved in the storage and diffusion of nutrients and cell movement. HA is mainly synthesized by hyaluronic acid synthase (HAS) in keratinocytes and fibroblasts and accumulates in the extracellular matrix. Three types of HAS genes known so far have been reported: HAS-1, HAS-2, and HAS-3. Defects in the moisture barrier due to reduced expression of these genes include epidermal atrophy, wrinkle formation, decreased skin moisture content, and decreased elasticity. It has been reported to cause skin aging. Among these, the HAS-3 gene is known to be closely related to the chemical barrier function of the skin.
상기 화학적 장벽 기능은 각질세포 간 지질의 투과 장벽 기능과 피부 표면의 낮은 산성도(pH 5.5), 각질층 내 항균 펩타이드 등에 의해 유지된다. 피부에서 분비되는 항균 펩타이드에는 디펜신(human β-defensin-1, 2, 3)과 cathelicidin, secretory leukocyte proteinase inhibitor, dermcidin, adrenomedullin 등이 있다. 이러한 항균 펩타이드는 감염이나 염증반응에 의해 급격하게 증가하면서 일차적인 방어기능을 수행하고, 2차적으로 호중구, 비만세포, 단핵구 등과 같은 면역 세포를 활성화하여 면역을 증진하는 화학 장벽 기능을 수행한다. 만성 피부질환에서 높은 세균 감염율을 보이는 것은 이러한 항균성 펩타이드의 발현의 저하와 관련 있는 것으로 보고되었다.The chemical barrier function is maintained by the permeability barrier function of lipids between keratinocytes, the low acidity of the skin surface (pH 5.5), and antibacterial peptides in the stratum corneum. Antibacterial peptides secreted from the skin include defensins (human β-defensin-1, 2, and 3), cathelicidin, secretory leukocyte proteinase inhibitor, dermcidin, and adrenomedullin. These antibacterial peptides rapidly increase due to infection or inflammatory response, performing a primary defense function, and secondarily performing a chemical barrier function that promotes immunity by activating immune cells such as neutrophils, mast cells, and monocytes. It has been reported that the high rate of bacterial infection in chronic skin diseases is related to a decrease in the expression of these antibacterial peptides.
한편, 사포나린(saponarin)은 새싹보리, 무궁화 등에 함유되어 있는 기능성 물질로 플라본 글루코사이드이다. 최근 연구 결과에 따르면 사포나린(saponarin)은 폴리페놀의 일종으로 식물성 생리활성물질이며, 당분해 효소를 억제하여 혈당을 낮추고 인슐린 저항성을 예방하여 알코올성 지방간 예방 또는 개선효과가 뛰어난 것으로 알려져 있다.Meanwhile, saponarin is a flavone glucoside and is a functional substance contained in barley sprouts and Rose of Sharon. According to recent research results, saponarin is a type of polyphenol and is a plant-based physiologically active substance. It is known to have an excellent effect in preventing or improving alcoholic fatty liver disease by lowering blood sugar and preventing insulin resistance by inhibiting glycolytic enzymes.
또한, 영지버섯(Ganoderma lucidum)은 불로초과(Ganodermataceae)에 속하며, 불로초, 만년버섯 등으로 불리며, 한국, 일본, 중국 등 북반구 온대 이북에 분포한다. 여름부터 가을까지 활엽수의 생목밑동이나 그루터기 위에 군생 또는 단생하는 근주심재 부후성 버섯으로, 여러 가지 아미노산과 수용성 단백질, 스테로이드물질, 안트라퀴논 유도체, 탄수화물, 각종 배당체, 소량의 알칼로이드 환원성 물질들과 리그닌을 분해하는 효소를 함유하고 있다. 영지버섯은 부작용이 없으며, 항암효과, 조압작용, 정혈작용, 감당작용, 이뇨작용, 해독작용 등 170여 가지의 각종 질환의 치료 및 예방에 유효하여 약용으로 널리 이용되고 있으며, 영지버섯에서 유래된 다당류는 종양에 대한 비특이적인 능동 면역을 부여할 수 있는 생체반응 조절물질로 인식되고 있다(Shimura, K. et al., Japan. J. Pharmac., 33:403, 1983). 또한 영지버섯 균사체 배양물로부터 추출·분리된 다당체는 미생물 및 종양세포에 대한 직접적인 세포독성과 대식세포 활성에 따른 숙주의 면역기능이 활성화되어 면역능을 높이는 작용에 의해 항미생물작용과 항암작용을 가진다고 보고되고 있다.In addition, Ganoderma lucidum belongs to the Ganodermataceae family and is called the herb of elixir of life, the eternal mushroom, etc., and is distributed in the northern temperate zone of the northern hemisphere, including Korea, Japan, and China. It is a rotting mushroom that grows in groups or singly on the stumps or stumps of broad-leaved trees from summer to fall. It contains various amino acids, water-soluble proteins, steroid substances, anthraquinone derivatives, carbohydrates, various glycosides, small amounts of alkaloid reducing substances, and lignin. Contains enzymes that decompose. Reishi mushrooms have no side effects and are widely used for medicinal purposes as they are effective in the treatment and prevention of over 170 different diseases, including anti-cancer effects, blood pressure regulating effects, blood purifying effects, sugar-cooling effects, diuretic effects, and detoxification effects. Polysaccharides are recognized as biological response regulators that can confer non-specific active immunity against tumors (Shimura, K. et al., Japan. J. Pharmac., 33:403, 1983). In addition, polysaccharides extracted and isolated from reishi mushroom mycelium cultures are reported to have antimicrobial and anticancer effects through direct cytotoxicity against microorganisms and tumor cells and by activating the host's immune function through macrophage activity to increase immune function. It is becoming.
본 발명의 영지버섯 추출물과 사포나린을 함께 포함하는 조성물은 로리크린 (loricrin, LOR), 히알루론산 합성효소-1(hyaluronic acid synthase-1, HAS-1) 및 히알루론산 합성효소-3(hyaluronic acid synthase-3, HAS-3) 유전자의 발현을 증가시켜 피부장벽 강화용 조성물로서 효과적으로 이용될 수 있음을 확인하고 본 발명을 완성하였다.The composition containing the reishi mushroom extract and saponarin of the present invention contains loricrin (LOR), hyaluronic acid synthase-1 (HAS-1), and hyaluronic acid synthase-3 (hyaluronic acid). The present invention was completed after confirming that it can be effectively used as a composition for strengthening the skin barrier by increasing the expression of the (synthase-3, HAS-3) gene.
본 발명의 목적은 영지버섯(Ganoderma lucidum) 추출물과 폴리페놀의 일종인 사포나린(saponarin)을 유효성분으로 포함하는 피부장벽 강화용 화장료 조성물을 제공하는데 있다.The purpose of the present invention is to provide a cosmetic composition for strengthening the skin barrier containing Ganoderma lucidum extract and saponarin, a type of polyphenol, as active ingredients.
또한, 본 발명의 다른 목적은 영지버섯(Ganoderma lucidum) 추출물과 폴리페놀의 일종인 사포나린(saponarin)을 유효성분으로 포함하는 피부장벽 강화용 식품 조성물을 제공하는데 있다.Another object of the present invention is to provide a food composition for strengthening the skin barrier containing Ganoderma lucidum extract and saponarin, a type of polyphenol, as active ingredients.
또한, 본 발명의 다른 목적은 영지버섯(Ganoderma lucidum) 추출물과 폴리페놀의 일종인 사포나린(saponarin)을 유효성분으로 포함하는 피부장벽 강화용 건강기능식품 조성물을 제공하는데 있다.In addition, another object of the present invention is to provide a health functional food composition for strengthening the skin barrier containing Ganoderma lucidum extract and saponarin, a type of polyphenol, as active ingredients.
상기 목적을 달성하기 위해 본 발명은 영지버섯 추출물과 폴리페놀의 일종인 사포나린을 유효성분으로 포함하는 피부장벽 강화용 화장료 조성물을 제공한다.To achieve the above object, the present invention provides a cosmetic composition for strengthening the skin barrier containing reishi mushroom extract and saponarin, a type of polyphenol, as active ingredients.
이어서, 본 발명은 영지버섯 추출물과 폴리페놀의 일종인 사포나린을 유효성분으로 포함하는 피부장벽 강화용 식품 또는 건강식품 조성물을 제공한다.Next, the present invention provides a food or health food composition for strengthening the skin barrier containing a reishi mushroom extract and saponarin, a type of polyphenol, as active ingredients.
본 발명의 영지버섯 추출물과 폴리페놀의 일종인 사포나린을 혼합하여 사용하는 경우, 영지버섯 추출물 또는 사포나린을 단독으로 사용하는 경우와 비교하여 로리크린 (loricrin, LOR), 히알루론산 합성효소-1 (hyaluronic acid synthase-1, HAS-1) 및 히알루론산 합성효소-3 (hyaluronic acid synthase-3, HAS-3) 유전자의 발현을 현저히 증가시키므로 피부장벽 강화용 조성물로 사용될 수 있다.When using a mixture of the reishi mushroom extract of the present invention and saponarin, a type of polyphenol, loricrin (LOR) and hyaluronic acid synthase-1 are compared to when the reishi mushroom extract or saponarin is used alone. Since it significantly increases the expression of (hyaluronic acid synthase-1, HAS-1) and hyaluronic acid synthase-3 (hyaluronic acid synthase-3, HAS-3) genes, it can be used as a composition for strengthening the skin barrier.
도 1은 본 발명의 일 실시예에 있어서, 사람 피부 각질 형성 세포(human keratinocyte cell)에 대한 사포나린의 세포독성을 나타낸 그래프이다.
도 2는 본 발명의 일 실시예에 있어서, 사람 피부 각질 형성 세포(human keratinocyte cell)에 대한 영지버섯 추출물의 세포독성을 나타낸 그래프이다.
도 3은 본 발명의 일 실시예에 있어서, 사람 피부 각질 형성 세포(human keratinocyte cell)에 대한 영지버섯 추출물 및 사포나린의 세포독성을 나타낸 그래프이다.
도 4는 본 발명의 일 실시예에 있어서, 사람 피부 각질 형성 세포(human keratinocyte cell)에 대한 영지버섯 추출물과 사포나린을 함께 처리시의 피부장벽 기능 관련 유전자인 로리크린(loricrin, LOR), 히알루론산 합성효소-1(hyaluronic acid synthase-1, HAS-1) 및 히알루론산 합성효소-3(hyaluronic acid synthase-3, HAS-3) 유전자의 발현 분석 결과를 나타낸 그래프이다.Figure 1 is a graph showing the cytotoxicity of saponarin on human keratinocyte cells according to an embodiment of the present invention.
Figure 2 is a graph showing the cytotoxicity of a reishi mushroom extract on human skin keratinocyte cells according to an embodiment of the present invention.
Figure 3 is a graph showing the cytotoxicity of reishi mushroom extract and saponarin on human keratinocyte cells according to an embodiment of the present invention.
Figure 4 shows, in an embodiment of the present invention, loricrin (LOR), a gene related to skin barrier function, and hyaluronic acid when human skin keratinocyte cells are treated together with reishi mushroom extract and saponarin. This graph shows the results of expression analysis of hyaluronic acid synthase-1 (HAS-1) and hyaluronic acid synthase-3 (HAS-3) genes.
이하, 본 발명에 대하여 보다 상세하게 설명하도록 한다.Hereinafter, the present invention will be described in more detail.
본 발명에서 사용되는 용어(terminology)들은 본 발명의 바람직한 실시예를 적절히 표현하기 위해 사용된 용어들로서, 이는 사용자, 운용자의 의도 또는 본 발명이 속하는 분야의 관례 등에 따라 달라질 수 있다. 따라서, 본 용어들에 대한 정의는 본 명세서 전반에 걸친 내용을 토대로 내려져야 할 것이다. 명세서 전체에서, 어떤 부분이 어떤 구성요소를 "포함"한다고 할 때, 이는 특별히 반대되는 기재가 없는 한 다른 구성요소를 제외하는 것이 아니라 다른 구성 요소를 더 포함할 수 있는 것을 의미한다.The terminology used in the present invention is a term used to appropriately express preferred embodiments of the present invention, and may vary depending on the intention of the user or operator or the customs of the field to which the present invention belongs. Therefore, definitions of these terms should be made based on the content throughout this specification. Throughout the specification, when a part is said to “include” a certain element, this means that it may further include other elements rather than excluding other elements, unless specifically stated to the contrary.
본 발명에서 사용되는 모든 기술용어는, 달리 정의되지 않는 이상, 본 발명의 관련 분야에서 통상의 당업자가 일반적으로 이해하는 바와 같은 의미로 사용된다. 또한 본 명세서에는 바람직한 방법이나 시료가 기재되나, 이와 유사하거나 동등한 것들도 본 발명의 범주에 포함된다. 본 명세서에 참고문헌으로 기재되는 모든 간행물의 내용은 본 발명에 도입된다.All technical terms used in the present invention, unless otherwise defined, are used with the same meaning as commonly understood by a person skilled in the art in the field related to the present invention. In addition, preferred methods and samples are described in this specification, but similar or equivalent methods are also included in the scope of the present invention. The contents of all publications incorporated by reference herein are hereby incorporated by reference.
본 발명의 영지버섯 추출물과 사포나린의 혼합 조성물은 사람 피부 각질 형성 세포(human keratinocyte cell)에 독성을 띄지 않는 조건에서 이의 피부 물리적 장벽 내지 화학적 장벽의 수준을 유의하게 증가시켜 피부장벽 강화 효과를 제공할 수 있다.The mixed composition of reishi mushroom extract and saponarin of the present invention provides a skin barrier strengthening effect by significantly increasing the level of the skin's physical barrier and chemical barrier under conditions that are not toxic to human keratinocyte cells. can do.
따라서, 본 발명은 영지버섯(Ganoderma lucidum) 추출물과 폴리페놀의 일종인 사포나린(saponarin)을 유효성분으로 포함하는 피부장벽 강화용 화장료 조성물을 제공한다.Therefore, the present invention provides a cosmetic composition for strengthening the skin barrier containing Ganoderma lucidum extract and saponarin, a type of polyphenol, as active ingredients.
본 발명에서 사용되는 용어 “사포나린(saponarin)”은 분자식 C27H30O15를 갖는 플라보노이드이며, 식물의 2차 대사산물이다. 또한 사포나린은 주로 새싹 작물에 포함되어 있는 것으로 알려져 있다. 특히 보리 새싹, 보리순 또는 청보리 등에 함유되어 있는 것으로 보고되었다. 플라보노이드는 당-연결 글리코사이드 및 아글리콘(aglycone)을 포함하며, 아글리콘과 부착된 당 부분의 다른 조합에 의해 여러 플라보노이드가 자연적으로 발생한다.The term “saponarin” used in the present invention is a flavonoid with the molecular formula C 27 H 30 O 15 and is a secondary metabolite of plants. Additionally, saponarin is known to be mainly contained in sprout crops. In particular, it has been reported to be contained in barley sprouts, barley sprouts, or green barley. Flavonoids include sugar-linked glycosides and aglycones, and several flavonoids occur naturally with different combinations of aglycones and attached sugar moieties.
본 발명에서 사용되는 용어 “영지버섯(Ganoderma lucidum)”은 담자균류 민주름버섯목 구멍장이버섯과의 1년생 버섯으로, 여름에서 가을에 걸쳐 활엽수 뿌리 밑동이나 그루터기에서 주로 자란다. 한방에서는 심신을 안정시켜주고 기혈을 보충해주며 기침을 진정시키는 등의 효능이 있어 신경쇠약·불면증·어지러움증·오래된 기침 등에 사용한다. 암과 관련된 연구도 진행되고 있으며, 일부 동물실험에서 영지가 암의 성장을 억제한다는 결과가 보고된 바 있다.The term “ Ganoderma lucidum ” used in the present invention is an annual mushroom of the Basidiomycete order Asteraceae family, which mainly grows at the base of the roots or stumps of broad-leaved trees from summer to fall. In Oriental medicine, it has the effect of stabilizing the mind and body, replenishing energy and blood, and soothing coughs, so it is used for nervous breakdown, insomnia, dizziness, and long-term coughing. Research related to cancer is also being conducted, and some animal experiments have reported that reishi suppresses the growth of cancer.
또한, 상기 조성물은 피부장벽 기능 관련 유전자인 로리크린(loricrin, LOR), 히알루론산 합성효소-1(hyaluronic acid synthase-1, HAS-1), 히알루론산 합성효소-3(hyaluronic acid synthase-3, HAS-3) 유전자의 발현을 증가시키는 것일 수 있다.In addition, the composition contains genes related to skin barrier function, such as loricrin (LOR), hyaluronic acid synthase-1 (HAS-1), and hyaluronic acid synthase-3. It may increase the expression of the HAS-3) gene.
또한, 상기 조성물은 피부장벽 기능을 강화시키는 것일 수 있다.Additionally, the composition may strengthen the skin barrier function.
본 발명에서 사용되는 용어 “로리크린(loricrin)”은 피부 각질의 껍질을 구성하고 있는 단백질 중 하나로, 글리신, 세린, 메티오닌이 풍부하며 피부 장벽 기능에 관여하는 단백질을 의미한다. 이 단백질에 결함이 있으면 여러 가지 각화 이상 질환이 발생하는 것으로 알려져 있다.The term “loricrin” used in the present invention refers to a protein that constitutes the shell of skin keratin, is rich in glycine, serine, and methionine, and is involved in skin barrier function. It is known that defects in this protein cause various keratinization disorders.
본 발명에서 사용되는 용어 “히알루론산”은 글루코사민글라이칸(glycosaminoglycan)의 하나이다. 히알루론산은 N-아세틸 글루코사민(N-acetyl glucosamine)과 글루쿠론산(Glucuronic acid)으로 이루어지는데, 히알루론산 합성효소(hyaluronic acid synthase, HAS)를 통해 합성되며 합성 과정 중에는 세포외기질에 축적된다. 조직의 수분 유지, 세포 성장인자 및 영양성분의 저장 및 확산에 관여하며, 각질형성세포와 섬유아세포에 의해 합성되는 것으로 알려져 있다. 피부 내 히알루론산의 감소는 피부탄력 감소 및 주름 증가의 원인으로 알려져 있다.The term “hyaluronic acid” used in the present invention is one of glucosamine glycans (glycosaminoglycan). Hyaluronic acid is composed of N-acetyl glucosamine and glucuronic acid. It is synthesized through hyaluronic acid synthase (HAS) and accumulates in the extracellular matrix during the synthesis process. It is involved in maintaining tissue moisture, storing and spreading cell growth factors and nutrients, and is known to be synthesized by keratinocytes and fibroblasts. A decrease in hyaluronic acid in the skin is known to cause decreased skin elasticity and increased wrinkles.
본 발명에서 사용되는 용어 “히알루론산 합성효소(hyaluronic acid synthase)”는 히알루론산을 합성하는 효소 단백질로, 히알루론산은 동물 등의 피부에 많이 존재하는 생체 합성 천연 물질이다. 히알루론산 합성효소-1(HAS-1), 히알루론산 합성효소-2(HAS-2) 및 히알루론산 합성효소-3(HAS-3)이 알려져 있으며, 특히 HAS-3는 섬유아세포와 각질형성세포에서 히알루론산 합성에 중요한 역할을 한다고 알려져 있다. The term “hyaluronic acid synthase” used in the present invention refers to an enzyme protein that synthesizes hyaluronic acid, and hyaluronic acid is a biosynthetic natural substance that is abundant in the skin of animals and other animals. Hyaluronic acid synthase-1 (HAS-1), hyaluronic acid synthase-2 (HAS-2), and hyaluronic acid synthase-3 (HAS-3) are known, and in particular, HAS-3 is used in fibroblasts and keratinocytes. It is known to play an important role in the synthesis of hyaluronic acid.
따라서, 피부 내 히알루론산 함량 유지는 피부보습, 피부탄력 유지에 중요한 역할을 한다.Therefore, maintaining the hyaluronic acid content in the skin plays an important role in maintaining skin moisturization and skin elasticity.
또한, 상기 사포나린은 5 내지 80 μg/mL 농도로 포함될 수 있으나, 이에 제한되는 것은 아니다.Additionally, the saponarin may be included at a concentration of 5 to 80 μg/mL, but is not limited thereto.
또한, 상기 영지버섯 추출물은 50 내지 1000 μg/mL 농도로 포함될 수 있으나, 이에 제한되는 것은 아니다.Additionally, the reishi mushroom extract may be included at a concentration of 50 to 1000 μg/mL, but is not limited thereto.
또한, 상기 영지버섯 추출물은 물, C1 내지 C4 알코올 또는 이들의 혼합용매로 추출한 것일 수 있으며, 바람직하게는 물로 추출한 것일 수 있다.Additionally, the reishi mushroom extract may be extracted with water, C 1 to C 4 alcohol, or a mixed solvent thereof, and preferably may be extracted with water.
본 발명의 “화장료 조성물”은 상술한 본 발명의 사포나린의 화장품학적 유효량(cosmetically effective amount) 및 화장품학적으로 허용되는 담체를 포함하여 제조할 수 있다.The “cosmetic composition” of the present invention can be prepared by containing a cosmetically effective amount of the saponarin of the present invention described above and a cosmetically acceptable carrier.
본 명세서에서 용어 “화장품학적 유효량”은 상술한 본 발명의 조성물의 표피 각질형성세포의 증식을 통한 피부 재생 효능을 달성하는 데 충분한 양을 의미한다.As used herein, the term “cosmetically effective amount” refers to an amount sufficient to achieve the skin regenerative effect through proliferation of epidermal keratinocytes of the composition of the present invention described above.
화장료 조성물의 외형은 화장품학 또는 피부과학적으로 허용 가능한 매질 또는 기제를 함유한다. 이는 국소적용에 적합한 모든 제형으로, 예를 들면, 용액, 겔, 고체, 반죽 무수 생성물, 수상에 유상을 분산시켜 얻은 에멀젼, 현탁액, 마이크로에멀젼, 마이크로캡슐, 미세과립구 또는, 이온형(리포좀) 및 비이온형의 소낭 분산제의 형태로, 또는 크림, 스킨, 로션, 파우더, 연고, 스프레이 또는 콘실 스틱의 형태로 제공될 수 있다. 이들 조성물은 당해 분야의 통상적인 방법에 따라 제조될 수 있다. 본 발명에 따른 조성물은 또한 포말(foam)의 형태로 또는 압축된 추진제를 더 함유한 에어로졸 조성물의 형태로도 사용될 수 있다.The appearance of the cosmetic composition contains a cosmetically or dermatologically acceptable medium or base. These are all formulations suitable for topical application, such as solutions, gels, solids, pasty anhydrous products, emulsions obtained by dispersing the oil phase in the water phase, suspensions, microemulsions, microcapsules, microgranules or ionic forms (liposomes) and It may be provided in the form of a non-ionic vesicular dispersion, or in the form of a cream, skin, lotion, powder, ointment, spray or concealer stick. These compositions can be prepared according to conventional methods in the art. The composition according to the invention can also be used in the form of a foam or in the form of an aerosol composition further containing a compressed propellant.
본 발명의 일 실시예에 따른 상기 화장료 조성물은 그 제형에 있어서 특별히 한정되는 바가 없으며, 예를 들면, 유연화장수, 수렴화장수, 영양화장수, 영양크림, 마사지크림, 에센스, 아이크림, 아이에센스, 클렌징크림, 클렌징폼, 클렌징워터, 팩, 파우더, 바디로션, 바디크림, 바디오일 및 바디에센스 등의 화장품으로 제형화될 수 있다.The cosmetic composition according to an embodiment of the present invention is not particularly limited in its formulation, and includes, for example, softening lotion, astringent lotion, nourishing lotion, nourishing cream, massage cream, essence, eye cream, eye essence, and cleansing lotion. It can be formulated into cosmetics such as cream, cleansing foam, cleansing water, pack, powder, body lotion, body cream, body oil, and body essence.
본 발명의 화장료 조성물의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물섬유, 식물섬유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is a paste, cream or gel, animal fiber, vegetable fiber, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide, etc. are used as carrier ingredients. This can be used.
본 발명의 화장료 조성물의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the cosmetic composition of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder can be used as the carrier ingredient. In particular, when the cosmetic composition is a spray, chlorofluorohydride may be used additionally. May contain propellants such as carbon, propane/butane or dimethyl ether.
본 발명의 화장료 조성물의 제형이 용액 또는 유탁액의 경우에는 담체 성분으로서 용매, 용매화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the cosmetic composition of the present invention is a solution or emulsion, a solvent, solvating agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene. These include fatty acid esters of glycol, 1,3-butylglycol oil, glycerol aliphatic esters, polyethylene glycol or sorbitan.
본 발명의 화장료 조성물의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is a suspension, the carrier component includes water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester, Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracant may be used.
본 발명의 화장료 조성물의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 리놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is a surfactant-containing cleansing agent, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, and sarcosinate are used as carrier ingredients. , fatty acid amide ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, linoline derivative, or ethoxylated glycerol fatty acid ester can be used.
본 발명의 화장료 조성물은 스킨, 로션, 크림, 에센스, 팩, 파운데이션, 색조화장품, 선크림, 투웨이케이크, 페이스파우더, 콤팩트, 메이크업베이스, 스킨커버, 아이쉐도우, 립스틱, 립글로스, 립픽스, 아이브로우 펜슬, 화장수 등의 화장품 및 샴푸, 비누 등의 세정제에 적용될 수 있다.The cosmetic composition of the present invention includes skin, lotion, cream, essence, pack, foundation, color cosmetics, sunscreen, two-way cake, face powder, compact, makeup base, skin cover, eye shadow, lipstick, lip gloss, lip fix, and eyebrow pencil. , can be applied to cosmetics such as lotion and detergents such as shampoo and soap.
본 발명의 일 실시예에 따른 화장료 조성물에는 상기 영지버섯 추출물 및 사포나린 이외에 기능성 첨가물 및 일반적인 화장료 조성물에 포함되는 성분이 추가로 포함될 수 있다. 상기 기능성 첨가물로는 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당, 스핑고 지질 및 해초 엑기스로 이루어진 군에서 선택된 성분을 포함할 수 있다.The cosmetic composition according to an embodiment of the present invention may further include functional additives and components included in general cosmetic compositions in addition to the reishi mushroom extract and saponarin. The functional additive may include ingredients selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, sphingolipids, and seaweed extract.
본 발명의 화장료 조성물에는 또한, 상기 기능성 첨가물과 더불어 필요에 따라 일반적인 화장료 조성물에 포함되는 성분을 배합해도 된다. 이외에 포함되는 배합 성분으로서는 유지 성분, 보습제, 에몰리엔트제, 계면 활성제, 유기 및 무기 안료, 유기 분체, 자외선 흡수제, 방부제, 살균제, 산화 방지제, 식물 추출물, pH 조정제, 알콜, 색소, 향료, 혈행 촉진제, 냉감제, 제한(制汗)제, 정제수 등을 들 수 있다.In addition to the above-mentioned functional additives, the cosmetic composition of the present invention may also contain components included in general cosmetic compositions, if necessary. Other ingredients included include oils and fats, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, disinfectants, antioxidants, plant extracts, pH adjusters, alcohol, pigments, fragrances, and blood circulation agents. Examples include accelerators, cooling agents, restrictors, and purified water.
이어서, 본 발명은 영지버섯(Ganoderma lucidum) 추출물과 폴리페놀의 일종인 사포나린(saponarin)을 유효성분으로 포함하는 피부장벽 강화용 식품 또는 건강식품 조성물을 제공한다.Next, the present invention provides a food or health food composition for strengthening the skin barrier containing Ganoderma lucidum extract and saponarin, a type of polyphenol, as active ingredients.
상기 영지버섯 추출물과 사포나린은 상기 피부장벽 강화용 화장료 조성물에 포함되는 것과 동일하므로 설명은 그 기재로 대신한다.Since the reishi mushroom extract and saponarin are the same as those included in the cosmetic composition for strengthening the skin barrier, the description will be replaced by their description.
본 발명의 식품 조성물은 유효성분인 영지버섯 추출물과 사포나린을 함유하는 것 외에 통상의 식품 조성물과 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다.In addition to containing the active ingredients Ganoderma lucidum extract and saponarin, the food composition of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients like a typical food composition.
상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨,소르비톨, 에리트리톨 등의 당알콜이다. 상술한 향미제는 천연 향미제(타우마틴), 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 본 발명의 식품 조성물은 상기 약학적 조성물과 동일한 방식으로 제제화되어 기능성 식품으로 이용하거나, 각종 식품에 첨가할 수 있다. 본 발명의 조성물을 첨가할 수 있는 식품으로는 예를 들어, 음료류, 육류, 초코렛, 식품류, 과자류, 피자, 라면, 기타 면류, 껌류, 사탕류, 아이스크림류, 알코올 음료류, 비타민 복합제 및 건강보조식품류 등이 있다.Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose, etc.; Disaccharides such as maltose, sucrose, etc.; and polysaccharides, such as common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. The above-described flavoring agents include natural flavoring agents (thaumatin), stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.), and synthetic flavoring agents (saccharin, aspartame, etc.). The food composition of the present invention can be formulated in the same way as the pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, meat, chocolate, foods, confectionery, pizza, ramen, other noodles, gum, candy, ice cream, alcoholic beverages, vitamin complexes, health supplements, etc. There is.
또한, 상기 식품 조성물은 유효성분인 추출물 외에 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 식품 조성물은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다.In addition, the food composition contains, in addition to the extract as the active ingredient, various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavors, colorants and thickening agents (cheese, chocolate, etc.), pectic acid, and salts thereof. , alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. In addition, the food composition of the present invention may contain pulp for the production of natural fruit juice, fruit juice beverages, and vegetable beverages.
본 발명의 기능성 식품 조성물은, 정제, 캅셀, 분말, 과립, 액상, 환 등의 형태로 제조 및 가공될 수 있다. 본 발명에서 '건강기능성식품 조성물'이라 함은 건강기능식품에 관한 법률 제6727호에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 말하며, 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다. 본 발명의 건강기능성식품은 통상의 식품 첨가물을 포함할 수 있으며, 식품 첨가물로서의 적합 여부는 다른 규정이 없는 한, 식품의약품안전청에 승인된 식품 첨가물 공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다. 상기 '식품 첨가물 공전'에 수재된 품목으로는 예를 들어, 케톤류, 글리신, 구연산칼슘, 니코틴산, 계피산 등의 화학적 합성물; 감색소, 감초추출물, 결정셀룰로오스, 고량색소, 구아검 등의 천연첨가물; L-글루타민산나트륨 제제, 면류첨가알칼리제, 보존료 제제, 타르색소제제 등의 혼합제제류 등을 들 수 있다. 예를 들어, 정제 형태의 건강기능성식품은 본 발명의 유효성분을 부형제, 결합제, 붕해제 및 다른 첨가제와 혼합한 혼합물을 통상의 방법으로 과립화한 다음, 활택제 등을 넣어 압축성형하거나, 상기 혼합물을 직접 압축 성형할 수 있다. 또한 상기 정제 형태의 건강기능성식품은 필요에 따라 교미제 등을 함유할 수도 있다. 캅셀 형태의 건강기능성식품 중 경질 캅셀제는 통상의 경질 캅셀에 본 발명의 유효성분을 부형제 등의 첨가제와 혼합한 혼합물을 충진하여 제조할 수 있으며, 연질 캅셀제는 본 발명의 유효성분을 부형제 등의 첨가제와 혼합한 혼합물을 젤라틴과 같은 캅셀기제에 충진하여 제조할 수 있다. 상기 연질 캅셀제는 필요에 따라 글리세린 또는 소르비톨 등의 가소제, 착색제, 보존제 등을 함유할 수 있다. 환 형태의 건강기능성식품은 본 발명의 유효성분과 부형제, 결합제, 붕해제 등을 혼합한 혼합물을 기존에 공지된 방법으로 성형하여 조제할 수 있으며, 필요에 따라 백당이나 다른 제피제로 제피할 수 있으며, 또는 전분, 탈크와 같은 물질로 표면을 코팅할 수도 있다. 과립 형태의 건강기능성식품은 본 발명의 유효성분의 부형제, 결합제, 붕해제 등을 혼합한 혼합물을 기존에 공지된 방법으로 입상으로 제조할 수 있으며, 필요에 따라 착향제, 교미제 등을 함유할 수 있다.The functional food composition of the present invention can be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc. In the present invention, 'health functional food composition' refers to food manufactured and processed using raw materials or ingredients with functionality useful to the human body in accordance with Act No. 6727 on Health Functional Food, and refers to food that has It means taking it for the purpose of controlling nutrients or obtaining useful health effects such as physiological effects. The health functional food of the present invention may contain common food additives, and its suitability as a food additive is determined in accordance with the general provisions of the Food Additives Code and General Test Methods approved by the Food and Drug Administration, unless otherwise specified. Judgment is made according to specifications and standards. Items listed in the 'Food Additive Code' include, for example, chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; Natural additives such as dark pigment, licorice extract, crystalline cellulose, high-quality pigment, and guar gum; Examples include mixed preparations such as sodium L-glutamate preparations, noodle additive alkaline preparations, preservative preparations, and tar coloring preparations. For example, health functional foods in the form of tablets are prepared by granulating a mixture of the active ingredient of the present invention with excipients, binders, disintegrants, and other additives in a conventional manner, adding a lubricant, etc., and compression molding, or The mixture can be directly compression molded. Additionally, the health functional food in the form of tablets may contain flavoring agents, etc., if necessary. Among capsule-type health functional foods, hard capsules can be manufactured by filling a regular hard capsule with a mixture of the active ingredient of the present invention mixed with additives such as excipients, and soft capsules can be prepared by mixing the active ingredient of the present invention with additives such as excipients. It can be manufactured by filling the mixture with a capsule base such as gelatin. The soft capsule may contain plasticizers such as glycerin or sorbitol, colorants, preservatives, etc., if necessary. The health functional food in the form of a ring can be prepared by molding a mixture of the active ingredient of the present invention, excipients, binders, disintegrants, etc., using a known method. If necessary, it can be coated with white sugar or other coating agents. Alternatively, the surface can be coated with substances such as starch or talc. Health functional food in the form of granules can be manufactured into granules by mixing a mixture of excipients, binders, disintegrants, etc. of the active ingredients of the present invention by a known method, and may contain flavoring agents, flavoring agents, etc., if necessary. You can.
본 발명에 따른 건강기능식품 조성물은 당업계에 공지된 통상적인 방법에 따라 다양한 형태로 제조할 수 있다. 일반 식품으로는 이에 한정되지 않지만 음료(알콜성 음료 포함), 과실 및 그의 가공식품(예: 과일통조림, 병조림, 잼, 마아말레이드 등), 어류, 육류 및 그 가공식품(예: 햄, 소시지 콘비이프 등), 빵류 및 면류(예: 우동, 메밀국수, 라면, 스파게이트, 마카로니 등), 과즙, 각종 드링크, 쿠키, 엿, 유제품(예: 버터, 치이즈 등), 식용식물 유지, 마아가린, 식물성 단백질, 레토르트 식품, 냉동식품, 각종 조미료(예: 된장, 간장, 소스 등) 등에 본 발명의 영지버섯 추출물과 사포나린을 첨가하여 제조할 수 있다. 또한, 영양보조제로는 이에 한정되지 않지만 캡슐, 타블렛, 환 등에 본 발명의 영지버섯 추출물과 사포나린을 첨가하여 제조할 수 있다. 또한, 건강기능식품으로는 이에 한정되지 않지만 예를 들면, 본 발명의 영지버섯 추출물과 사포나린 자체를 차, 쥬스 및 드링크의 형태로 제조하여 음용(건강음료)할 수 있도록 액상화, 과립화, 캡슐화 및 분말화하여 섭취할 수 있다. 또한, 본 발명의 영지버섯 추출물 및 사포나린을 식품 첨가제의 형태로 사용하기 위해서는 분말 또는 농축액 형태로 제조하여 사용할 수 있다. 또한, 본 발명의 영지버섯 추출물과 사포나린과 피부보습 증진, 피부탄력 증진 및 피부보호 효과가 있다고 알려진 공지의 활성 성분과 함께 혼합하여 조성물의 형태로 제조할 수 있다.The health functional food composition according to the present invention can be manufactured in various forms according to conventional methods known in the art. General foods include, but are not limited to, beverages (including alcoholic beverages), fruits and their processed foods (e.g. canned fruit, bottled foods, jam, mamalade, etc.), fish, meat and their processed foods (e.g. ham, sausages, etc.) corned beef, etc.), bread and noodles (e.g. udon, buckwheat noodles, ramen, spagate, macaroni, etc.), fruit juice, various drinks, cookies, taffy, dairy products (e.g. butter, cheese, etc.), edible vegetable oil, margarine , vegetable proteins, retort foods, frozen foods, various seasonings (e.g., soybean paste, soy sauce, sauce, etc.), etc. can be produced by adding the reishi mushroom extract and saponarin of the present invention. In addition, nutritional supplements are not limited to this, but can be prepared by adding the reishi mushroom extract and saponarin of the present invention to capsules, tablets, pills, etc. In addition, health functional foods are not limited to this, but for example, the reishi mushroom extract of the present invention and saponarin itself can be manufactured in the form of tea, juice, and drinks and liquefied, granulated, and encapsulated so that they can be consumed (health drinks). And it can be powdered and consumed. Additionally, in order to use the reishi mushroom extract and saponarin of the present invention in the form of food additives, they can be prepared and used in the form of powder or concentrate. In addition, it can be prepared in the form of a composition by mixing the reishi mushroom extract of the present invention with saponarin and known active ingredients known to have skin moisturizing, skin elasticity, and skin protection effects.
본 발명의 영지버섯 추출물과 사포나린을 건강음료로 이용하는 경우, 상기 건강음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드; 말토스, 슈크로스와 같은 디사카라이드; 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드; 자일리톨, 소르비톨, 에리트리톨 등의 당알콜일 수 있다. 감미제는 타우마틴, 스테비아 추출물과 같은 천연 감미제; 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 mL 당 일반적으로 약 0.01 ~ 0.04 g, 바람직하게는 약 0.02 ~ 0.03 g 이다.When the reishi mushroom extract and saponarin of the present invention are used as a health drink, the health drink composition may contain various flavoring agents or natural carbohydrates as additional ingredients like ordinary drinks. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; polysaccharides such as dextrins and cyclodextrins; It may be a sugar alcohol such as xylitol, sorbitol, or erythritol. Sweeteners include natural sweeteners such as thaumatin and stevia extract; Synthetic sweeteners such as saccharin and aspartame can be used. The proportion of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g, per 100 mL of the composition of the present invention.
또한, 본 발명의 영지버섯 추출물과 사포나린은 피부장벽 강화용 식품 조성물의 유효성분으로 함유될 수 있는데, 그 양은 피부장벽 강화를 달성하기에 유효한 양으로 특별히 한정되는 것은 아니나, 전체 조성물 총 중량에 대하여 0.01 내지 100 중량%인 것이 바람직하다. 본 발명의 건강기능식품 조성물은 영지버섯 추출물과 사포나린과 함께 피부장벽 강화 효과가 있는 것으로 알려진 다른 활성 성분과 함께 혼합하여 제조될 수 있다.In addition, the reishi mushroom extract and saponarin of the present invention can be contained as active ingredients in a food composition for strengthening the skin barrier, and the amount is not particularly limited to an amount effective to achieve skin barrier strengthening, but is included in the total weight of the entire composition. It is preferably 0.01 to 100% by weight. The health functional food composition of the present invention can be prepared by mixing reishi mushroom extract and saponarin with other active ingredients known to have a skin barrier strengthening effect.
상기 외에 본 발명의 건강기능식품은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산, 펙트산의 염, 알긴산, 알긴산의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올 또는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 건강기능식품은 천연 과일주스, 과일주스 음료, 또는 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 혼합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량부당 0.01 ~ 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the health functional food of the present invention includes various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, and preservatives. , may contain glycerin, alcohol, or carbonating agent. In addition, the health functional food of the present invention may contain pulp for the production of natural fruit juice, fruit juice beverage, or vegetable beverage. These ingredients can be used independently or in combination. The ratio of these additives is not very important, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
이하, 본 발명의 실시예를 첨부된 도면을 참고하여 보다 상세하게 설명하도록 한다. 그러나, 하기의 실시예는 본 발명의 내용을 구체화 하기 위한 것일 뿐, 이에 의해 본 발명이 한정되는 것은 아닐 것이다.Hereinafter, embodiments of the present invention will be described in more detail with reference to the attached drawings. However, the following examples are only intended to embody the content of the present invention and are not intended to limit the present invention thereto.
<실시예 1> 영지버섯 추출물의 제조<Example 1> Preparation of reishi mushroom extract
영지버섯 추출물을 제조하기 위해, 분쇄된 80g의 영지버섯 및 3차 증류수 1.2L을 혼합한 혼합물을 80 ℃에서 2 시간 동안 2회 환류 추출하고 여과 후 감압 농축하여 영지버섯 추출물을 제조하였다.To prepare a reishi mushroom extract, a mixture of 80 g of pulverized reishi mushrooms and 1.2 L of tertiary distilled water was refluxed and extracted twice for 2 hours at 80°C, filtered, and concentrated under reduced pressure to prepare a reishi mushroom extract.
<실시예 2> 세포 독성 확인<Example 2> Confirmation of cytotoxicity
2-1. 사포나린의 세포 독성 확인2-1. Confirmation of cytotoxicity of saponarin
사포나린이 사람 피부 각질 형성 세포(human keratinocyte cell)에 독성을 띄는지 여부를 확인하고자 하였다.We sought to determine whether saponarin is toxic to human skin keratinocyte cells.
구체적으로, HaCaT 세포를 DMEM 배지에 10% 소 태아 혈청(FBS) 및 1% 항생제(페니실린 및 스트렙토마이신)를 첨가하고 37 ℃, 5% CO2에서 배양하였다. 배양된 세포를 10% FBS가 함유된 DMEM으로 24-웰 플레이트에 웰 당 5 × 104 세포로 37 ℃(5% CO2)에서 24 시간 동안 부착시킨 후 농도별 사포나린(5, 10, 20, 30, 40, 60 및 80 μg/mL)을 처리하여 24 시간 배양 후 배지에 MTT(3-(4,5-dimethylthiazol-2-y1)-2-5-diphenyltetrazolium bromide)를 첨가하고 암조건에서 2 시간 동안 추가 배양 하였다. 배양 후 배지를 제거하고, dimethyl sulfoxide(DMSO) 200 ㎕를 첨가하여 570 nm 흡광도를 측정하여 하기 수학식 1으로 세포 생존율을 확인하였다. 그 결과는 도 1에 나타내었다.Specifically, HaCaT cells were cultured in DMEM medium with 10% fetal bovine serum (FBS) and 1% antibiotics (penicillin and streptomycin) at 37°C and 5% CO 2 . Cultured cells were attached to a 24 -well plate with DMEM containing 10% FBS at 5 , 30, 40, 60, and 80 μg/mL) and cultured for 24 hours, MTT (3-(4,5-dimethylthiazol-2-y1)-2-5-diphenyltetrazolium bromide) was added to the medium and incubated in dark conditions. Further incubation was carried out for 2 hours. After incubation, the medium was removed, 200 ㎕ of dimethyl sulfoxide (DMSO) was added, absorbance at 570 nm was measured, and cell viability was confirmed using Equation 1 below. The results are shown in Figure 1.
도 1에 나타낸 바와 같이, 5 내지 80 μg/mL 농도의 사포나린 처리는 HaCaT 세포의 생존율에 영향을 미치지 않는 것을 확인할 수 있었다.As shown in Figure 1, it was confirmed that saponarin treatment at a concentration of 5 to 80 μg/mL did not affect the survival rate of HaCaT cells.
[수학식 1][Equation 1]
세포 생존율 (%) = (대조군 흡광도/실험군 흡광도)×100 Cell viability (%) = (control group absorbance/experimental group absorbance)×100
2-2. 영지버섯 추출물의 세포 독성 확인2-2. Confirmation of cytotoxicity of reishi mushroom extract
실시예 1의 영지버섯 추출물이 사람 피부 각질 형성 세포(human keratinocyte cell, HaCaT)에 독성을 띄는지 여부를 확인하고자 하였다. 실험방법은 실시예 2-1의 방법과 동일하게 수행하였으며, 50, 100, 200, 400, 500, 800, 1000 μg/mL 농도의 영지버섯 추출물을 사용하였다. 그 결과는 도 2에 나타내었다.An attempt was made to determine whether the reishi mushroom extract of Example 1 was toxic to human skin keratinocyte cells (HaCaT). The experimental method was performed in the same manner as in Example 2-1, and reishi mushroom extracts were used at concentrations of 50, 100, 200, 400, 500, 800, and 1000 μg/mL. The results are shown in Figure 2.
도 2에 나타낸 바와 같이, 50 내지 1000 μg/mL 농도의 영지버섯 추출물의 처리는 HaCaT 세포의 생존율에 영향을 미치지 않는 것을 확인할 수 있었다.As shown in Figure 2, it was confirmed that treatment with reishi mushroom extract at a concentration of 50 to 1000 μg/mL did not affect the survival rate of HaCaT cells.
2-3. 영지버섯 추출물 및 사포나린 혼합물의 세포 독성 확인2-3. Confirmation of cytotoxicity of reishi mushroom extract and saponarin mixture
다양한 농도의 영지버섯 추출물 및 사포나린을 혼합한 혼합물의 사람 피부 각질 형성 세포(human keratinocyte cell, HaCaT)에 독성을 띄는지 여부를 확인하고자 하였다. 실험방법은 상기 실시예 2-1의 방법과 동일하게 수행하였으며, 혼합물은 각각의 영지버섯 추출물 및 사포나린을 동일한 농도로 제조하였다.We sought to determine whether a mixture of various concentrations of reishi mushroom extract and saponarin was toxic to human keratinocyte cells (HaCaT). The experimental method was performed in the same manner as in Example 2-1, and the mixture was prepared with the same concentrations of each reishi mushroom extract and saponarin.
<실시예 3> 피부 장벽 보호 기능 유전자 발현 분석<Example 3> Skin barrier protection function gene expression analysis
세포 생존율에 영향을 미치지 않는 농도의 사포나린 처리에 따른 사람 피부 각질 형성 세포(human keratinocyte cell, HaCaT)의 물리적 장벽 관련 유전자인 LOR 및 HAS-1과 화학적 장벽 관련 유전자인 HAS-3 발현량을 확인하고자 하였다.The expression levels of LOR and HAS-1, the physical barrier-related genes, and HAS-3, the chemical barrier-related gene, of human keratinocyte cells (HaCaT) were confirmed following treatment with saponarin at a concentration that does not affect cell viability. I wanted to do it.
구체적으로, 실험에는 80 μg/mL 농도의 사포나린, 80 μg/mL 농도의 영지버섯 추출물 및 이들의 혼합물이 사용되었으며, HaCaT 세포의 총 RNA는 TRIzol 시약을 사용하여 추출하였으며, 1 ㎍의 RNA를 oligo-dT 프라이머 및 ImProm-II reverse transcriptase와 혼합하고 42 ℃에서 60 분 동안 반응하여 cDNA를 합성하였다. cDNA 1 ㎕를 12.5 ㎕의 Sensi-FAST SYBR No_ROX 및 10 pmol의 피부 장벽 관련 유전자 특이 프라이머와 혼합한 후 최종 25 ㎕의 반응액으로 95 ℃에서 3분 1 회, 95 ℃에서 5초, 60 ℃에서 10초로 40회 및 최종 72 ℃에서 15초 반응하여 정량 PCR 분석을 수행하였다. 그 결과는 도 4에 나타내었다.Specifically, saponarin at a concentration of 80 μg/mL, reishi mushroom extract at a concentration of 80 μg/mL, and mixtures thereof were used in the experiment. Total RNA from HaCaT cells was extracted using TRIzol reagent, and 1 μg of RNA was extracted. cDNA was synthesized by mixing with oligo-dT primer and ImProm-II reverse transcriptase and reacting at 42°C for 60 minutes. After mixing 1 ㎕ of cDNA with 12.5 ㎕ of Sensi-FAST SYBR No_ROX and 10 pmol of skin barrier-related gene-specific primer, the final 25 ㎕ of the reaction solution was incubated once at 95 °C for 3 minutes, at 95 °C for 5 seconds, and at 60 °C. Quantitative PCR analysis was performed with 40 reactions of 10 seconds each and a final reaction of 15 seconds at 72°C. The results are shown in Figure 4.
도 4에 나타낸 바와 같이, 영지버섯 추출물 및 사포나린을 혼합한 혼합물은 LOR, HAS-1, HAS-3 유전자의 발현을 유의하게 증가시켰다. 특히, 영지버섯 추출물 및 사포나린을 혼합한 혼합물은 대조군(영지버섯 추출물 및 사포나린이 처리되지 않은 실험군) 뿐만 아니라 영지버섯 추출물 및 사포나린을 단독으로 사용한 경우와 비교하여 LOR 및 HAS-1 유전자의 발현을 2배 이상 증가시켰다.As shown in Figure 4, the mixture of reishi mushroom extract and saponarin significantly increased the expression of LOR, HAS-1, and HAS-3 genes. In particular, the mixture of reishi mushroom extract and saponarin was compared to the control group (experimental group not treated with reishi mushroom extract and saponarin) as well as the case where reishi mushroom extract and saponarin were used alone, compared to the LOR and HAS-1 genes. Expression was increased more than 2-fold.
이러한 결과는 영지버섯 추출물 및 사포나린을 혼합한 혼합물은 LOR, HAS-1 및 HAS-3 유전자의 발현을 유의적인 수준에서 증가시키므로 피부세포 내 로리크린 및 히알루론산을 증가시켜 피부보습, 피부탄력 또는 피부보호용 조성물로 유용하게 이용될 수 있을 뿐만 아니라, 영지버섯 추출물 및 사포나린을 혼합할 경우, 단독으로 사용한 경우와 비교하여 현저히 우수한 피부보습 증진, 피부탄력 증진 및 피부 장벽 기능 강화 효과를 가진다는 것을 의미한다.These results show that the mixture of reishi mushroom extract and saponarin significantly increases the expression of LOR, HAS-1, and HAS-3 genes, thereby increasing loricrin and hyaluronic acid in skin cells, thereby improving skin moisturization, skin elasticity, and Not only can it be useful as a skin protection composition, but when mixed with reishi mushroom extract and saponarin, it has significantly better skin moisturizing, skin elasticity, and skin barrier function strengthening effects compared to when used alone. it means.
이상에서 살펴본 바와 같이, 본 발명의 구체적인 실시예를 상세하게 설명되었으나, 본 발명의 사상을 이해하는 당업자는 동일한 사상의 범위 내에서 다른 구성요소를 추가, 변경, 삭제 등을 통하여, 퇴보적인 다른 발명이나 본 발명 사상의 범위 내에 포함되는 다른 실시예를 용이하게 제안할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다. 본 발명의 범위는 상술한 상세한 설명보다는 후술하는 특허청구의 범위에 의하여 나타내어지며, 특허청구의 범위의 의미 및 범위 그리고 그 균등 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.As discussed above, specific embodiments of the present invention have been described in detail, but those skilled in the art who understand the spirit of the present invention may add, change, delete, etc. other components within the scope of the same spirit, thereby creating other regressive inventions. However, other embodiments that are included within the scope of the present invention can be easily proposed. Therefore, the embodiments described above should be understood in all respects as illustrative and not restrictive. The scope of the present invention is indicated by the scope of the claims described below rather than the detailed description above, and all changes or modified forms derived from the meaning and scope of the claims and their equivalent concepts are included in the scope of the present invention. It should be interpreted as
Claims (1)
상기 조성물은 로리크린(loricrin, LOR), 히알루론산 합성효소-1(hyaluronic acid synthase-1, HAS-1) 또는 히알루론산 합성효소-3(hyaluronic acid synthase-3, HAS-3) 유전자의 발현을 증가시키는 것을 특징으로 하는, 피부장벽 강화용 화장료 조성물.In a cosmetic composition for strengthening the skin barrier containing reishi mushroom water extract and saponarin as active ingredients,
The composition inhibits the expression of loricrin (LOR), hyaluronic acid synthase-1 (HAS-1) or hyaluronic acid synthase-3 (HAS-3) genes. A cosmetic composition for strengthening the skin barrier, characterized in that it increases the skin barrier.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200103275 | 2020-08-18 | ||
| KR20200103275 | 2020-08-18 | ||
| KR1020200167364A KR102557706B1 (en) | 2020-08-18 | 2020-12-03 | Composition for skin-protective comprising saponarin and Ganoderma lucidum extract |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200167364A Division KR102557706B1 (en) | 2020-08-18 | 2020-12-03 | Composition for skin-protective comprising saponarin and Ganoderma lucidum extract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20230110475A KR20230110475A (en) | 2023-07-24 |
| KR102632743B1 true KR102632743B1 (en) | 2024-02-02 |
Family
ID=80490335
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200167364A KR102557706B1 (en) | 2020-08-18 | 2020-12-03 | Composition for skin-protective comprising saponarin and Ganoderma lucidum extract |
| KR1020230091896A KR102632743B1 (en) | 2020-08-18 | 2023-07-14 | Composition for strengthening skin barrier containing Ganoderma lucidum extract as an active ingredient |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200167364A KR102557706B1 (en) | 2020-08-18 | 2020-12-03 | Composition for skin-protective comprising saponarin and Ganoderma lucidum extract |
Country Status (1)
| Country | Link |
|---|---|
| KR (2) | KR102557706B1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102143230B1 (en) | 2019-11-29 | 2020-08-11 | 대봉엘에스 주식회사 | Cosmetic composition comprising green barley sprout extract |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR950002777A (en) * | 1993-07-26 | 1995-02-16 | 노리오 소메야 | Bioactive Substances Extracted from Coral Sands |
| KR970058704A (en) * | 1997-01-20 | 1997-08-12 | 이진학 | Manufacturing method of skin massage cream with added ganoderma lucidum |
| KR100886090B1 (en) * | 2008-01-02 | 2009-02-27 | 오세권 | Manufacturing method of health supplement food composition using sprout vegetable fermentation broth |
| KR101868050B1 (en) * | 2011-10-25 | 2018-06-18 | (주)아모레퍼시픽 | Fermentation method using medicinal flower and skin external composition containing fermented extract by the method |
| JP5952256B2 (en) * | 2013-12-27 | 2016-07-13 | 株式会社東洋新薬 | Beauty composition |
| KR20170062854A (en) * | 2015-11-30 | 2017-06-08 | 에스엘 주식회사 | Lamp for vehicle |
| KR101862231B1 (en) * | 2016-09-07 | 2018-05-30 | 주식회사 코리아나화장품 | Cosmetic composition for preventing near infrared ray containing extract of ganoderma lucidum |
| KR102137951B1 (en) * | 2018-09-10 | 2020-07-27 | 윤성준 | Cosmetic composition with skin soothing effect comprising mushroom complex extract, and manufacturing method thereof |
-
2020
- 2020-12-03 KR KR1020200167364A patent/KR102557706B1/en active IP Right Grant
-
2023
- 2023-07-14 KR KR1020230091896A patent/KR102632743B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102143230B1 (en) | 2019-11-29 | 2020-08-11 | 대봉엘에스 주식회사 | Cosmetic composition comprising green barley sprout extract |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102557706B1 (en) | 2023-07-24 |
| KR20230110475A (en) | 2023-07-24 |
| KR20220022427A (en) | 2022-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101861043B1 (en) | Composition for Improving Skin Wrinkles Using an Extract of Penthorum chinense | |
| KR101936294B1 (en) | Composition comprising for skin-whitening and anti-wrinkling extract of Rumex acetosella L. or extract of Hydrangea serrata | |
| KR101743200B1 (en) | Composition for skin whitening comprising fraction of fruit extract of Sageretia thea as effective component | |
| KR101821024B1 (en) | COMPOSITION OF SKIN WHITENING CONTAINING EXTRACT OF Gloiopeltis Furcata AND METHOD OF MAKING THE SAME | |
| KR101474998B1 (en) | Composition comprising extracts of white tea for the care of skin wrinkle | |
| KR20190061544A (en) | Cosmetic Composition for Anti-oxidation and Whitening comprising fermented silkworm extract as effective component | |
| KR101772494B1 (en) | COMPOSITION OF SKIN WHITENING CONTAINING EXTRACT OF Sargassum horneri AND METHOD OF MAKING THE SAME | |
| KR101188682B1 (en) | Composition for skin whitening comprising extracts of Veronica longiofolia L. | |
| KR102077708B1 (en) | Composition for skin-whitening and anti-winkle comprising extract of Poria cocos, Coix lachrymajobi and Stachys sieboldii fermented using Hericium erinaceum mycelium as effective component | |
| KR20200083293A (en) | Cosmetic composition comprising mixture of fermented extract of Cirsium japonicum and Moringa oleifera | |
| KR102632743B1 (en) | Composition for strengthening skin barrier containing Ganoderma lucidum extract as an active ingredient | |
| KR20200074361A (en) | Composition for skin whitening and composition for ultraviolet-proof comprising the extract of fermented Astragalus membranaceus Bunge | |
| KR102167319B1 (en) | Composition for Improving Skin Trouble Using an Extract of Coprs Cultured with Magma Seawater, etc. | |
| KR102154139B1 (en) | Composition comprising fermentation of sap of painted maple, cacao nibs extract and granat extract | |
| KR102331119B1 (en) | Composition for preventing skin anti-aging comprising fermented black rice extract and fermented peanut sprout extract | |
| KR102128168B1 (en) | Composition comprising the extract of Lentinula edodes and Acer pictum subsp. mono leaf for antioxidant effect | |
| KR101964837B1 (en) | Composition for improving skin wrinkle comprising Cynomorium songaricum extract or its fraction as effective component | |
| KR20220077991A (en) | Composition for anti-inflammation and anti-wrinkle comprising fermentative product of Gryllus bimaculatus extract as effective component | |
| KR20210056714A (en) | Cosmetic Composition Containing extract of Pleurotus citrinopileatus and Broussonetia kazinoki branch for anti-aging | |
| KR102449136B1 (en) | Compositions containing Taraxacum coreanum extract | |
| KR102481095B1 (en) | Inner beauty composition for anti-wrinkle containing red sea cucumber and fish collagen | |
| KR102548612B1 (en) | Compositions for Improving Skin Wrinkles and for Skin Moisturizing Using an Extract of Parsnip | |
| KR102401490B1 (en) | Compositions containing Angelica gigas extract | |
| KR102355138B1 (en) | Composition for whitening or anti-wrinkle of the skin comprising fermentated ziziphus jujuba seed as effective component | |
| KR102105897B1 (en) | Skin whitening composition comprising Ainsliaea acerifolia extract produced by ultra high pressure homogenization as effective component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |